The Liver Meeting 2024 - Debrief Sessions - Portuguese-Alcohol Liver Disease Debrief Session

Video Transcription

Video Summary

Juan Pablo Arab, an Associate Professor at Virginia Commonwealth University, presents on advances in alcohol-associated liver disease (ALD) research. Preclinical findings highlight the gut-liver axis's role in ALD, with promising targets like intestinal mucin II and myeloperoxidase for treatment. GLP-1 receptor agonists show potential for reducing liver injury in ALD models, warranting further investigation. Mitochondrial dysfunction in ALD, linked to PDK4, emerges as another therapeutic target.<br /><br />This UK study delved into differentiating metabolic-associated ALD (MetALD) from other profiles, finding significant roles for specific metabolites. Clinical discussions noted metabolic factors, like obesity and diabetes, affecting ALD outcomes. Studies revealed disparities in alcohol use disorder trends and the unmet needs for better management and intervention, including brief interventions with transient elastography leading to reduced alcohol intake.<br /><br />Potential therapies like GLP-1 and varenicline show promise, and changes in prescribing patterns for treatments like corticosteroids demonstrate evolving practices. Recommendations for ALD treatment include combining pharmacological approaches with psychosocial interventions to improve patient outcomes.

Keywords

alcohol-associated liver disease

gut-liver axis

GLP-1 receptor agonists

metabolic-associated ALD

mitochondrial dysfunction

therapeutic targets